NIP
GTHX

Nicholas Investment Partners’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Nicholas Investment Partners’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,976
Closed -$208K – 247
2018
Q3 		$208K Buy
+3,976
New +$217K 0.02% 216

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nicholas Investment Partners's GTHX Position: Q4 2018 in Review

Nicholas Investment Partners sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2018, closing a stake of 3,976 shares — an estimated $208K sold.

Nicholas Investment Partners first reported a position in GTHX in Q3 2018 and held it in 1 quarter. The position peaked at $208K in Q3 2018. 93 funds tracked by Wall St. Rank hold GTHX as of Q4 2018.

  • Nicholas Investment Partners reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Nicholas Investment Partners sold 3,976 G1 Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $208K.
  • Nicholas Investment Partners first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Nicholas Investment Partners's G1 Therapeutics, Inc. Common Stock position peaked at $208K in Q3 2018.
  • 93 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Nicholas Investment Partners's 13F filing for Q4 2018, filed 14 Feb 2019.